CLASS II Device recall · Reported 10 Nov 2021 · FDA Enforcement Report

Atellica IM Sars-CoV-2 Antigen Assay (100 Test Kit), SMN # recalled

Siemens Healthcare Diagnostics is recalling Atellica IM Sars-CoV-2 Antigen Assay (100 Test Kit), SMN # 11207861, distributed nationwide in the US. The recall was initiated on 22 Sep 2021 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot # 44989001 - Exp. Date 2021-10-07, UDI # (01)00630414611846(10)44989001(17)20211007; Lot # 60407003 - Exp. Date 2021-03-22, UDI # (01)00630414611846(10)60407003(17)20211112.
Quantity recalled149 kits

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-0195-2022
FDA event ID
88768
Recalling firm
Siemens Healthcare Diagnostics, East Walpole, MA
Classification
Class II
Status
Terminated
Recall initiated
22 Sep 2021
FDA classified
3 Nov 2021
Reported
10 Nov 2021
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Potency & Assay

Timeline

22 Sep 2021Recall initiated by company
3 Nov 2021Classified by FDA+42 days
10 Nov 2021Published in enforcement report+7 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Data provided in the Emergency Use Authorization (EUA) submission was insufficient to determine that the assays were adequately validated for the intended use.

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

Atellica IM SARS-CoV-2 Antigen Assay (100 Test Kit), SMN # 11207861

Where it was distributed

US Nationwide distribution in the states of AK, CA, CO, DC, GA, IL, ME, NC, NV, NY, OR, PA, PR, VA and VI.

Nationwide AlaskaCaliforniaColoradoDistrict of ColumbiaGeorgiaIllinoisMaineNorth CarolinaNevadaNew YorkOregonPennsylvaniaPuerto RicoVirginia

Questions about this recall

Why was it recalled?

Data provided in the Emergency Use Authorization (EUA) submission was insufficient to determine that the assays were adequately validated for the intended use.

Which lots are affected?

Lot # 44989001 - Exp. Date 2021-10-07, UDI # (01)00630414611846(10)44989001(17)20211007; Lot # 60407003 - Exp. Date 2021-03-22, UDI # (01)00630414611846(10)60407003(17)20211112.

Where was it sold?

US Nationwide distribution in the states of AK, CA, CO, DC, GA, IL, ME, NC, NV, NY, OR, PA, PR, VA and VI.

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

Other products in this recall event

1 other product · FDA event 88768

This product is part of a recall event; the main page for the event is Advia Centaur Sars-CoV-2 Antigen Assay (100 Test Kit) recalled.

More recalls from Siemens Healthcare Diagnostics

All 694

Other Test Kits & Diagnostics recalls

All 2,656